IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanneken, A.
Right arrow Articles by Baird, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanneken, A.
Right arrow Articles by Baird, A.

Investigative Ophthalmology & Visual Science, Vol 36, 1192-1196, Copyright © 1995 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Soluble forms of the high-affinity fibroblast growth factor receptor in human vitreous fluid

A Hanneken and A Baird
Whittier Institute for Diabetes and Endocrinology, La Jolla, California, USA.

PURPOSE. Fibroblast growth factor-binding proteins (FGF-BPs) have been identified recently in blood and other biologic fluids and have been shown to be identical to a truncated form of the high-affinity cell surface FGF receptor. The authors examined the hypothesis that FGF-BPs also are present in human vitreous fluid. METHODS. Vitreous fluid obtained from 12 patients was incubated overnight with heparin- Sepharose, FGF-2 heparin-Sepharose, and wheat germ agglutinin (WGA)- Sepharose, a lectin known to bind to high-affinity FGF receptors. The precipitated proteins were characterized by immunoblotting using two FGF receptor antibodies raised to either the extracellular domain of FGFR-1 or the intracellular domain of FGFR-1. RESULTS. A 70- to 85-kd FGF-BP was detected in the vitreous in each of the 12 eyes examined. A 55-kd FGF-BP was detected in six of the samples. Both the 70-to 85-kDa and the 55-kDa proteins were precipitated by FGF-2 heparin-Sepharose but not by heparin-Sepharose alone, suggesting that the interaction was dependent on the presence of FGF-2. The proteins bound avidly to WGA- Sepharose. Western blot analysis revealed that the proteins were recognized by an antibody raised to the extracellular domain of the high-affinity FGF receptor but not by an antibody raised to the intracellular domain of the FGF receptor, indicating they are likely to be truncated portions of the extracellular domain of the high-affinity FGF receptor. CONCLUSIONS. Vitreous fluid contains 70- to 85-kd and 55- kd FGF-BPs that have biochemical and immunologic characteristics similar to the extracellular domain of the high-affinity FGF receptor. These naturally occurring FGF-BPs may sequester free FGF in the vitreous cavity and may modulate the biologic activity of FGF in vitreoretinal diseases.


This article has been cited by other articles:


Home page
 IOVSHome page
R. Ganti, R. C. Hunt, S. K. Parapuram, and D. M. Hunt
Vitreous Modulation of Gene Expression in Low-Passage Human Retinal Pigment Epithelial Cells
Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1853 - 1863.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. Aihara, J. D. Lindsey, and R. N. Weinreb
Enhanced FGF-2 Movement through Human Sclera after Exposure to Latanoprost
Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2554 - 2559.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. Lau, L. H. McGee, S. Zhou, K. G. Rendahl, W. C. Manning, J. A. Escobedo, and J. G. Flannery
Retinal Degeneration Is Slowed in Transgenic Rats by AAV-Mediated Delivery of FGF-2
Invest. Ophthalmol. Vis. Sci., October 1, 2000; 41(11): 3622 - 3633.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
T. P. Richardson, V. Trinkaus-Randall, and M. A. Nugent
Regulation of Basic Fibroblast Growth Factor Binding and Activity by Cell Density and Heparan Sulfate
J. Biol. Chem., May 7, 1999; 274(19): 13534 - 13540.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. A. Neely and T. W. Gardner
Ocular Neovascularization : Clarifying Complex Interactions
Am. J. Pathol., September 1, 1998; 153(3): 665 - 670.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Ozaki, N. Okamoto, S. Ortega, M. Chang, K. Ozaki, S. Sadda, M. A. Vinores, N. Derevjanik, D. J. Zack, C. Basilico, et al.
Basic Fibroblast Growth Factor Is Neither Necessary nor Sufficient for the Development of Retinal Neovascularization
Am. J. Pathol., September 1, 1998; 153(3): 757 - 765.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
L Cassidy, P Barry, C Shaw, M J Duffy, and S Kennedy
Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders
Br. J. Ophthalmol., February 1, 1998; 82(2): 181 - 185.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. J. Hill, A. Flyvbjerg, E. Arany, F. F. Lauszus, and J. G. Klebe
Increased Levels of Serum Fibroblast Growth Factor-2 in Diabetic Pregnant Women with Retinopathy
J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1452 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
M. Boulton, Z. Gregor, D. McLeod, D. Charteris, J. Jarvis-Evans, P. Moriarty, A. Khaliq, D. Foreman, D. Allamby, and B. Bardsley
Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management
Br. J. Ophthalmol., March 1, 1997; 81(3): 228 - 233.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Association for Research in Vision and Ophthalmology